关注
Yi-long Wu
Yi-long Wu
Professor of Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital
在 gdph.org.cn 的电子邮件经过验证
标题
引用次数
引用次数
年份
Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma
TS Mok, YL Wu, S Thongprasert, CH Yang, DT Chu, N Saijo, ...
New England Journal of Medicine 361 (10), 947-957, 2009
103042009
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang, S Zhang, J Wang, ...
The lancet oncology 12 (8), 735-742, 2011
50882011
The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer
P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ...
Journal of Thoracic Oncology 11 (1), 39-51, 2016
40882016
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ...
New England Journal of Medicine 368 (25), 2385-2394, 2013
40542013
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
New England Journal of Medicine 371 (23), 2167-2177, 2014
37012014
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TS Mok, YL Wu, MJ Ahn, MC Garassino, HR Kim, SS Ramalingam, ...
New England Journal of Medicine 376 (7), 629-640, 2017
34202017
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ...
The Lancet 393 (10183), 1819-1830, 2019
31532019
Lung cancer: current therapies and new targeted treatments
FR Hirsch, GV Scagliotti, JL Mulshine, R Kwon, WJ Curran, YL Wu, ...
The Lancet 389 (10066), 299-311, 2017
28702017
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open …
YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi, ...
The lancet oncology 15 (2), 213-222, 2014
24602014
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised …
JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ...
The lancet oncology 16 (2), 141-151, 2015
18832015
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically …
M Fukuoka, YL Wu, S Thongprasert, P Sunpaweravong, SS Leong, ...
Journal of clinical oncology 29 (21), 2866-2874, 2011
18552011
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M Krzakowski, E Laack, ...
The Lancet 374 (9699), 1432-1440, 2009
1831*2009
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
ES Kim, V Hirsh, T Mok, MA Socinski, R Gervais, YL Wu, LY Li, ...
The Lancet 372 (9652), 1809-1818, 2008
17472008
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...
New England Journal of Medicine 383 (18), 1711-1723, 2020
13912020
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ...
Cancer cell 17 (1), 77-88, 2010
12312010
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
12262017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho, F Tsuji, R Linke, ...
The Lancet Oncology 18 (11), 1454-1466, 2017
11552017
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 …
JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ...
The lancet oncology 16 (7), 830-838, 2015
9912015
Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma
ZY Dong, WZ Zhong, XC Zhang, J Su, Z Xie, SY Liu, HY Tu, HJ Chen, ...
Clinical cancer research 23 (12), 3012-3024, 2017
8622017
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open …
YL Wu, C Zhou, CK Liam, G Wu, X Liu, Z Zhong, S Lu, Y Cheng, B Han, ...
Annals of oncology 26 (9), 1883-1889, 2015
8012015
系统目前无法执行此操作,请稍后再试。
文章 1–20